Rockville, MD, United States, July 17, 2023 – Advanced BioScience Laboratories (ABL), a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) serving the US Government and biopharmaceutical industry, today announces it was awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract by the National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) of the National Institutes of Health (NIH), under the Diagnostics Preclinical Services program.

This seven-year contract (75N93023D00015) has a maximum funding value of $12 million. ABL will support the DMID in two task areas:

• Providing expertise in product development processes and documentation, ensuring the highest standards of quality and efficiency
• Leveraging its capabilities in the production and delivery of customized recombinant proteins and monoclonal antibodies, specifically designed for the construction of IVD assays

The accurate and sensitive detection of diseases is vital in healthcare and biomedical research; IVDs play a critical role in clinical decision-making for both individual patients and public health.

“ABL has a long-standing partnership with the NIH and we are honored to continue our collaboration through this prestigious contract,” said Timothy Fouts, vice-president, innovation and translation at ABL, Inc. “This fourth contract since 2021 confirms ABL’s role as a trusted partner of the US Government and the biopharmaceutical industry. It showcases ABL’s capabilities in product development, manufacturing and testing, and reinforces our commitment to providing comprehensive solutions in the field of diagnostics. This contract is a testament to ABL’s expertise and experience in supporting biomedical research and development.”

IVDs represent one of the fastest evolving and growing sectors in healthcare, with a global market that was estimated at $87.6 billion in 2020. As the demand for IVD expertise continues to rise, ABL recognizes the need for strategic planning and consulting support. Diagnostic reagents, which are essential components for building IVD assays, will receive dedicated attention from ABL’s experienced team of scientists and industry partners.

In the coming months, ABL will work closely with the NIH to fulfill the requirements of the contract. The CDMO will leverage its core capabilities in product development, GMP manufacturing and immunological testing to provide comprehensive support to the Diagnostics Preclinical Services program.

About the National Institutes of Health (NIH)

The NIH, the US medical research agency, includes 27 institutes and centers and is a component of the US Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical and translational medical research. It investigates the causes, treatments and cures for both common and rare diseases.

For more information about NIH and its programs, visit www.nih.gov

About ABL

ABL, Inc. is a global contract research and manufacturing organization dedicated to advancing therapeutics, vaccines and other biological products. It has extensive experience working with diverse organizations including industry, government and academic entities. ABL maintains global GMP facilities meeting US and European regulatory standards, providing manufacturing capabilities for the development and production of virus-based oncolytic therapies, gene therapies and viral vaccines. Our services include bulk drug substance, live virus fill/finish, process and assay development. We also support clients’ preclinical and clinical sample processing and testing needs through our immunological laboratories. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.

www.ablinc.com

Media and analysts contacts
Andrew Lloyd & Associates
Saffiyah Khalique | Emilie Chouinard
saffiyah@ala.associates – emilie@ala.associates
Tel:  UK +44 1273 952 481
US: +1 203 724 595
@ALA_Group